A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for ...

Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 trial designed to evaluate its anti-TIGIT therapy domvanalimab in gastric and ...

The Fishing Harpoon is a Polearm in The Legend of Zelda: Tears of the Kingdom. This item was meant for fishing, but its spearhead is sharp enough that it can be used as a weapon in a pinch. "A ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer. Arcus ...

Gilead and Arcus’ efforts to rebuild confidence in TIGIT as a drug target for cancer immunotherapies have shuffled forwards again, with new data showing signs of efficacy in a combination regimen used ...

Gilead Sciences has forged closer ties to its cancer drug partner Arcus Biosciences , although a licensing deal doesn't go as far as the takeover that some market commentators have been predicting.

Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. The study, which was being conducted in partnership with Gilead Sciences, aimed to ...

RCUS is now resetting its strategy after its Phase 3 STAR-221 was discontinued. This removes domvanalimab for upper-GI cancers as a key catalyst. Instead, they’ll focus now on Casdatifan (AB521), ...

"Harpoon with a tip made from a sharpened meteorite shard. Wielded by the claymen who infest dynastic remains. The blade emits a faint light and deals magic damage." The Clayman's Harpoon Default ...

Arcus BiosciencesRCUS stock plunged Friday, reversing a nearly 300% gain over the past eight months, after its Gilead SciencesGILD-partnered cancer regimen failed its Phase 3 test. The duo tested a ...